Canine ACTH Stimulation Testing Protocol Indications - IDEXX
IV Compounded based on individual prescriptions (contact Dechra) Any remaining product in the vial should be discarded as there is no in-use stability data for this product because it is a special. Also there is no information on whether the product can be frozen or thawed Synacthen aqueous (tetracosactide) 0.25 mg/mL in 1 mL ampoule a) 5
Download Canine ACTH Stimulation Testing Protocol Indications - IDEXX
Information
Domain:
Source:
Link to this page:
Documents from same domain
fax e-mail: DEXAMETHASONE SUPPRESSION TEST (LOW …
www.idexx.co.ukhyperadrenocorticism (Cushing’s disease). Note a) In most situations low dose dexamethasone suppression testing (LDDS) is regarded as the test of choice for diagnosis of hyperadrenocorticism in the dog. Reported sensitivities for LDDS for diagnosis of hyperadrenocorticism range from
HISTO/CYTOLOGY REQUEST FORM
www.idexx.co.ukSWCY Cytology & Culture & Sensitivity HISM Histology & Cytology on Smears HISK Histology & Complete Skin Examination HICY Histology & Cytology on Fluids Tissues to be submitted in 10% Neutral Buffered Formalin. Polypropylene tubes with fixative are available from the laboratory. Please do not push large tissues into small pots.
SMALL ANIMAL REQUEST FORM - IDEXX
www.idexx.co.ukPLEASE TICK IF YOU WISH FOR THE SCREEN TO BE NON INTERPRETED CHEMISTRY ABA Bile Acid - Fasting ABAS Bile Acid Stimulation …
Interpretive Summary - IDEXX
www.idexx.co.uko Psychogenic polydipsia • Overhydration • Drugs o Growth hormone • Artifacts (depending on method of analysis) o High concentrations of sodium fluoride and sodium citrate o Chloramphenicol o Severe lipemia Related Findings • Chronic, severe liver disease o Decreased albumin, cholesterol, glucose ...
Related documents
1151 PHARMACEUTICAL DOSAGE FORMS - USP
latam-edu.usp.orgchemical stability of the drug substance in the dosage form matrix must support the expiration dating for the commercially prepared dosage forms and a beyond-use date for a compounded dosage form. Test procedures for potency must be stability indicating (see Validation of Compendial Procedures á1225ñ). Degradation products should be quantified.
<1151> PHARMACEUTICAL DOSAGE FORMS - DrugFuture
www.drugfuture.comChange to read: physical stability, and performance over time. The chemical stability of the API in the dosage form matrix must support the expiration dating for the commercially prepared dosage 〈1151〉 PHARMACEUTICAL forms and a beyond-use date for a compounded dosage form. Test procedures for potency must be stability indicat-
Wh y purchase medicatio n fro m an F DA outsourcin g
www.olympiapharmacy.comBeyond Use Date (BUD): Olympia performs all necessary testing to provide the longest BUD in the industry. This testing is performed by independent 3rd party, CGMP facilities. It includes batch sterility, potency, endotoxin, method suitability, compatibility and advanced stability testing. Without these tests, a
STRENGTH AND STABILITY TESTING FOR COMPOUNDED …
www.usp.orgJan 13, 2014 · 1 STRENGTH AND STABILITY TESTING FOR COMPOUNDED PREPARATIONSi. USP Compounding Expert Committee:a Loyd V Allen Jr, PhD,b Gus S Bassani, PharmD,c Edmund J Elder Jr, PhD,d Alan F Parr, PharmDe a Correspondence should be addressed to: Rick Schnatz, PharmD, Manager Compounding and Healthcare Standards, …
BRIEFING 797 Pharmaceutical Compounding—Sterile …
www.usp.orginclude criteria for validated stability-indicating assays and testing for sterility, endotoxins, container-closure integrity, and particulate matter. The resource(s) are intended to guide correct interpretation and application of testing results. Minor editorial changes have been made to update the chapter to current . USP style. (CMP: J. Sun.)
795 PHARMACEUTICAL COMPOUNDING—NONSTERILE …
www.uspnf.comric Apparatus 〈1176〉, Stability Considerations in Dispensing compounded. Practice 〈1191〉, Written Prescription Drug Information— 3. Ingredients used in the formulation have their ex-Guidelines 〈1265〉, and all applicable compounding laws, …